Resistance to loop diuretics. Why it happens and what to do about it

Area of Science:

• Nephrology
• Clinical Pharmacology

Background:

• Loop diuretic resistance is a common clinical challenge.
• Response to loop diuretics depends on drug delivery, timing, and pharmacodynamics.
• Mechanisms of resistance vary across different patient populations.

Purpose of the Study:

• To elucidate the mechanisms of loop diuretic resistance in various clinical conditions.
• To identify pharmacokinetic and pharmacodynamic factors contributing to resistance.
• To outline strategies for overcoming diuretic resistance.

Main Methods:

• Review of studies on healthy subjects and patients with specific conditions (elderly, renal insufficiency, nephrotic syndrome, hepatic cirrhosis, congestive heart failure).
• Analysis of drug appearance in urine, renal blood flow, and diuretic-protein binding.
• Evaluation of pharmacokinetic and pharmacodynamic alterations.

Main Results:

• Prostaglandin synthesis inhibitors do not affect diuretic entry but blunt response.
• Elderly and renally impaired patients show pharmacokinetic resistance.
• Nephrotic syndrome and hepatic cirrhosis exhibit pharmacodynamic resistance.
• Congestive heart failure involves pharmacodynamic resistance (IV) or combined resistance (oral).

Conclusions:

• Diuretic resistance mechanisms are condition-specific, involving pharmacokinetic, pharmacodynamic, or combined factors.
• Strategies like dose escalation, frequent administration, continuous infusion, or combination therapy can overcome resistance.